UCL ADVANCED CENTRE FOR
Biochemical Engineering
In this issue
EPSRC Centre for Innovative Manufacturing
in Emergent Macromolecular Therapies
Developments
Responsive Bioprocessing Facility
Launch Day
New MSc Courses
VISION News
Company Engagement: GE Healthcare
Abbott Innovation University Challenge Success
ISSUE NINE | SEPTEMBER 2012
Contents
Editorial
Editorial2
Foreword by Professor Nigel Titchener-Hooker
Departmental News
People often ask me what academics “do” in their long
summer breaks. Those who know this department will
realise just how odd that question is! As this issue of
Bioprocessing Matters shows the staff and researchers are
all very busy right over the summer months. Summer 2012
promises to be an exceptionally busy time too.
In the early 1990’s Peter Dunnill had a vision to fund and build a totally
unique and self-contained Department of Biochemical Engineering on what
was essentially the remnants of a bomb-damaged section of College behind
the Cloisters. The plans were made but the funding shortfall meant that the
Advanced Centre for Biochemical Engineering (ACBE) had to share its space
with the Japanese pharmaceutical company Eisai. This worked well and enabled
us to develop on three sites; the Roberts Building and Foster Court being the
other two. This year and next will see Peter’s vision fulfilled as Biochemical
Engineering moves into the, now vacated, Bernard Katz Building. This represents
a huge challenge and a marvellous opportunity.
UCL has done much to help foster the discipline of biochemical engineering in
the UK. In this edition we talk about the recent award of a Doctoral Training
Centre, funded by EPSRC. Our vision is to use up to 75% of the PhD projects
to help establish a national network of bioprocess manufacturing research. It’s
an exciting initiative involving Manchester, Cambridge, Birmingham, Aston,
Strathclyde and Loughborough as the funding partners.
Hopefully the sun will be shining when you read this; at present it feels
distinctly autumnal! This summer we will all be busy taking the agenda for UCL
Biochemical Engineering forward. I hope you will enjoy reading about our plans
and look forward to an opportunity in the near future of sharing these with you
in person.
Have a super summer “break”!
3
EPSRC Centre for Innovative
Manufacturing in Emergent
Macromolecular Therapies
Developments5
VISION News
New MSc Courses
9
10
Abbott Innovation University
Challenge Success
12
Company Engagement:
GE Healthcare
14
Primary Recovery MBI®
15
MBI® Course Dates
16
Prof. Nigel Titchener-Hooker
Head of Department and Director of the Advanced Centre for Biochemical
Engineering
2
Departmental News
New directions for UCL
biocatalysis research
The growing interest in sustainable production of chemicals and pharmaceuticals
is a key strategic driver for UCL biocatalysis research. A new £1.1M grant from
the BBSRC Integrated Biorefining Research and Technology Club (IBTI Club)
provides added impetus for our work in this area. Distillers dried grain and
solubles (DDGS) is a by-product from distilleries and breweries which currently
has some value as a ruminant feed. However, with the dramatic increase in
DDGS production expected as a result of “first generation” biofuel production
facilities now under construction in the UK, there is a need to find new ways
to upgrade and add value to the various components of DDGS. The new IBTI
grant focusses on the selective fractionation of the carbohydrate and protein
fractions of DDGS and their bioconversion into added value products. The UCL
work will focus on the selective release of the protein fraction (Prof John Ward)
and the creation of ultra scale-down methods to investigate DDGS fractionation
(Prof Gary Lye). The grant links UCL with Prof David Leak (University of
Bath) who will investigate utilisation of the carbohydrate fraction, Dr Regina
Santos (University of Birmingham) who will investigate DDGS fractionation
using Super Critical CO2 methods and Dr Caroline Rymer (University of
Reading) who will examine the nutritional value of the DDGS remaining after
fractionation and conversion.
For further information please contact Prof Gary Lye at g.lye@ucl.ac.uk
EPSRC Global Engagement Grant
with India
The potential and promise of India as a hub for low-cost
manufacture of complex biological products such as vaccines
is being realised. Today, one of every two children in the world is immunised
with a vaccine manufactured in India.
It is to this purpose that the Department has received funding from the
EPSRC to engage with industry and academic groups in India working in the
field of vaccine development and manufacture. The scope is to develop closer ties
through joint research ventures and secondment opportunities.
In January 2013 we are planning a three month research exchange of two of
our researchers and will host two Indian researchers at UCL. Later in March/
April 2013 we are planning to deliver a Vaccine Development training event
in India. The Department has already delivered a very successful Vaccine
Development MBI training course and seeks to deliver an abridged version of the
course to Indian biotech and academic institutions. Attendance will be open to
all and UK/EU/US companies can use this opportunity to network with a wider
audience in India and raise their profile abroad.
For more information about this initiative, please contact
Dr Tarit Mukhopadhyay at t.mukhopadhyay@ucl.ac.uk
3
BRITS
The British Regen Industry Tool Set (BRITS) is
an industry driven project aimed at establishing reliable market data and creating
both detailed bioprocess economics models and higher level business models for
integration into a highly valuable and timely set of decisional tools. The individual
components will themselves be highly novel, and the final integrated tool set will
be a major step change for the cell therapy industry. BRITS will encompass the
entire supply chain. This will including direct links through the main innovation
routes available within the NHS. Via its wider business benefit activities BRITS will
interact with all the UK stakeholders to facilitate the uptake of the outputs of the
project and build and maintain the vital linkages between the diverse stakeholders
in order to promote the joined-up approach that will be required if the UK is
to be at the international forefront of cell therapy, not just scientifically but also
commercially.
For more information about BRITS, please contact Prof Chris Mason chris.
mason@ucl.ac.uk or Dr Suzanne Farid s.farid@ucl.ac.uk
EPSRC Manufacturing Fellowship Award
The Department of Biochemical Engineering has
won one of only four pilot EPSRC Manufacturing
Fellowships. Awarded to Dr Ajoy Velayudhan to work
with Prof Nigel Titchener-Hooker, over the five year
appointment it is hoped to establish, in the UK, a new
area of interdisciplinary research in the rational design of
processes for the cost-effective manufacture of therapeutic
proteins. Dr Velayudhan has an established academic as well as industrial track
record in the USA and will be joining UCL in the Autumn. The success is
particularly important to the EPSRC Centre for Innovative Manufacturing in
Emergent Macromolecular Therapies as it increases the breadth of the studies that
can be explored and the range of industry partners who will join the consortium.
The Advanced Centre for Biochemical
Engineering is moving
UCL Department
of bioChemiCaL engineering
Over the next two years Biochemical engineering will
consolidate in one place, the Bernard Katz Building.
This has been made possible by Eisai, a Japanese
pharmaceutical company, vacating the areas they
occupied in the building. Whilst the logistics represent
a huge challenge, to build for the future is superb.
The Bernard Katz Building is soon to become
home to this internationally leading department
Global themes
•
Theachievement
ofspeedfrom
discoveryto
outcome
•
Theharnessing
ofgenomics
•
Addressingthe
newgeneration
ofcomplex
materials
•
Makingthe
outcomes
affordable
•
Achieving
sustainability
Engineering global biological solutions
www.ucl.ac.uk/biochemeng
Poster_120404.indd 1
4
16/04/2012 13:04
The EPSRC Centre will hold it Annual Conference
‘Biomanufacturing: New Challenges & New Paradigms’ on the 18
September 2012.
Venue: UCL, Anatomy Building, Gower Street
Time
Event
10.00
Registration & Refreshments
10.30
EPSRC Centre Flagship Research. Nigel Titchener-Hooker/Paul
Dalby/Suzanne Farid, UCL
11.00
Keynote: Robotic Platform for Rapid Delivery of Personalised
Vaccines. Markus Zamponi, Bayer
11.20
Keynote: Implementation of Integrated Continuous Bioprocessing
for Biologics. Konstantin Konstantinov, Genzyme. tbc
11.40
Keynote: Single-use Technologies for the Manufacture of Vaccines.
GSK
12.00
Lunch and Poster Session
13.00
Responsive Bioprocess Facility (RBF) – Research & Training
Agenda. Gary Lye, UCL
13.15
Engineering Characterisation of Single-use Bioreactors for
Improved Process Predictability. Martina Micheletti, UCL
13.45
Evaluating the Cost-effectiveness of Single-use Technologies for
Cell Therapies. Suzanne Farid, UCL
14.15
RBF Tour 1/ Poster Session
15.00
Poster Session/ RBF Tour 2
15.45
Break
16.00
Plenary Vision: Portfolio Management: How to Maximise within
Resource Constraints. Jo Pisani, PwC
17.15
Reception
As can be seen from the agenda above, this dovetails with the launch of UCL
Biochemical Engineering’s Rapid Bioprocessing Facility (RBF)
5
EPSRC Centre
EPSRC Centre For
Innovative
Manufacturing in
Emergent
Macromolecular
Therapies
Developments
EPSRC Centre
On the day following the Conference there will EPSRC Centre User Group
& Advisory Board Meetings and a separate agenda (see below) for those
organisations interested in exploring possible mechanisms of involvement
with the RBF through e.g. our STAMP initiative (Single-use Technology for
Advanced Manufacturing Partnership).
Time
Event
10:00
Introduction
Summary of current activities and presentation of our
proposal for the future of RBF (GJL)
10:30
Suppliers Workshop Part 1
Scientific presentations
11:30
Open discussion
Future training and research needs
12:45
Feedback and closing remarks
13:00
Lunch
14:00
Suppliers Workshop Part 2
Equipment show case
15:30
Close
We look forward to welcoming you.
For further information about the EPSRC Centre please contact
Prof Nigel Titchener-Hooker at nigelth@ucl.ac.uk
For further information about the RBF please contact
Dr Tarit Mukhopadhyay at t.mukhopadhyay@ucl.ac.uk or
Dr Martina Micheletti at m.micheletti@ucl.ac.uk
6
www.epsrc-cim-macromoleculartherapies.ac.uk
We are proud to announce the launch
of a dedicated new website. Interested
parties can visit www.epsrc-cimmacromoleculartherapies.ac.uk for the
latest news and upcoming events. Visitors
to the website will find information about
the EPSRC Centre; its vision, research,
team profiles and various mechanisms
available for engaging with the centre.
There is also the facility to download
issues of the ‘Bioprocessing Matters’
Newsletter and browse photograph
galleries.
“The website will enable visitors to
gain invaluable insight into our research
and outreach activities through an easy‐
to‐use online portal. This will actively encourage and foster long-term research
partnerships and knowledge transfer between academics, industry and the
public for mutual benefit. It will also bring to life the energy being invested in
the EPSRC Centre and the numerous benefits to society of the research being
conducted here” said the EPSRC Centre’s Director Prof Nigel Titchener-Hooker.
EPSRC Centre E-bulletin
A new e-bulletin has also been launched
and this will provide up-to-the-minute
information on how to engage with us.
7
EPSRC Centre
Launch of a dedicated website for the EPSRC
Centre
EPSRC Centre
EPSRC Centre Briefings Series
Three excellent briefings have already taken place:
• May 28: ‘Novel Escherichia coli hosts for endotoxin free production of recombinant
proteins and plasmid DNA’. David Bramhill, Research Corporation
Technologies, Tucson, AZ, USA
• June 07: ‘Moving nanotechnology through clinical routine use: the case for
nanomedicines and the way ahead for an integrated Healthcare and Science
agenda’ was given by Professor Rogerio Gaspar, Faculty of Pharmacy at the
University of Lisboa, Portugal
• July 09: ‘Technology Development Activities’ by Dr Alex Berrill, Pfizer.
EPSRC Centre for Doctoral Training (CDT) in
Macromolecular Therapies
The focus of the recently awarded EPSRC CDT (3 cohorts of 5 PhD’s) will be
on manufacturing research and training required in the most rapidly developing
parts of the UK bio-centred pharmaceutical and healthcare biotechnology sector,
that have major implications for future medicine. Alignment to the EPSRC
Centre for Innovative Manufacturing in Emergent Macromolecular Therapies
will deliver increased national capability through training of the next generation
of highly skilled and talented bioprocess manufacturing researchers. Our aim
is to train bioprocess engineering leaders of the future who will underpin
translation of new scientific advances into safely produced, more selective,
therapies for currently intractable conditions at affordable costs. To achieve this
we will embed CDT PhDs within the vibrant research community of the top
UK Institutions and that of the EPSRC Centre for Innovative Manufacturing
in Emergent Macromolecular Therapies, to ensure that they benefit in terms
of impact and knowledge transfer from the links to research led companies.
The gearing in of these collaborations will enable the CDT to explore new and
emerging ideas in a training environment that draws on research excellence and
to create strong synergy between the Centre research programmes.
For further information about the EPSRC Centre CDT please contact
Dr Paul Dalby at p.dalby@ucl.ac.uk
8
VISION
“Connectivity is our strength”
The VISION programme aims to be the nexus for the leaders
of the biological sciences industry to hear and debate the latest
technological and business developments in the sector.
Briefings:
• 15th March: Roup Chandwani, Aggio Partners Ltd gave a particularly
interesting set of insights into ‘Managing Risk in the Bioprocess
Industries’. His thesis was that 90% of risk is created and driven by
people. He provided stimulating examples of team dynamics and their
implications for communication and risk.
• 15th May: We heard a wonderful briefing from Gunter Jagschies of GE
Healthcare on ‘Managing Manufacturing Economics’. He addressed
drivers of economic efficiency in manufacturing with the view to
identifying the “sweet spot” in the equation.
Senior Leadership Course
Our third Senior Leadership Course took place on the 23-25th May in
the UCL Roberts Building Executive Suite. Twelve senior industrial
delegates from the likes of BPL, CSL, Invitrogen, MSD Animal Health,
Polytherics and UCB heard strategic talks by a range of senior academics
and industrialists drawn from organisations such as Asia Healthcare &
Biotech Ltd, Axella LLC, Chromatherapeutics, GE Healthcare, IP Asset
LLP, PriceWaterhouse Coopers and Unicorn Biologics and participated in
a range of stimulating case studies and moderated roundtable sessions. Two
particular highlights of the course were the illuminating and entertaining
after-dinner speech ‘How leadership will change in a transparent world’ given
by Udo Vetter, Managing Director and Founder of UV-Cap GmbH & Co.
KG and the GE Truck Tour which highlighted the impact of single-use
technologies on biomanufacturing strategies.
Next VISION event
Our next VISION event will be held on the 18th September 2012 and is a
Business Briefing entitled ‘Portfolio Management: How to maximise within
resource constraints’. The speaker will be Jo Pisani, PriceWaterhouseCoopers
Management of a portfolio which minimises failures and promotes
successes is the holy grail of the biological sciences industry. In this talk the
speaker will address key issues which need careful attention on the way to
this objective.
For further information please contact Dr Karen Smith at
karen.smith@ucl.ac.uk or Prof Eli Keshavarz-Moore at
e.keshavarz-moore@ucl.ac.uk
9
New MSc Courses
New exciting streams in the MSc and Year 4 MEng Biochemical Engineering programmes have been introduced for
September 2012, tailored specifically for students with a biochemical engineering background. The new programmes will
expose students to state-of-the-art research in the biochemical engineering sector. The training will provide advanced skills
so that students can see how to apply their bioprocess engineering knowledge to a substantial range of industrially-relevant
challenges. Specifically, students will gain breadth from courses that illustrate the application of bioprocessing fundamentals
across sectors ranging from stem cells, synthetic biology and vaccines through to biorefineries. In addition the new courses
will provide greater depth in advanced design principles through new courses focusing on sustainability analysis for
biorefineries and advanced risk-reward analysis using bioprocess systems engineering tools. For more information about the new MSc programmes, please contact Dr Dan Bracewell at d.bracewell@ucl.ac.uk
UCL MSc in Biochemical Engineering
Modular structure refecting the different entry points to the programme
Biochemical Eng. Graduates
Engineering Graduates
Science Graduates
Taught courses
Emerging Bioprocess Sectors
& Applications
• Industrial synthetic biology
• Biorefineries & sustainability
• Cell therapy bioprocessing
Vaccines or Bioprocess microfluidics
Advanced Life Sciences
• Microbial metabolism & engineering
• Structural biology & protein design
• Cell biochemistry: gene to metabolisis
• Applied molecular biology
Advanced Bioprocess Engineering
Emerging Bioprocess Sectors
& Applications
• Bioprocess synthesis and mapping
• Heat & mass transfer in bioprocesses
• Fluid flow & mixing in bioprocesses
• Process analysis & mass balancing
Advanced Biochemical Engineering
• Bioprocess systems engineering
• Validation & quality control (QbD)
Options: e.g. Project management
Process dynamics / Advanced safety
• Bioreactor design & fermentation
• Integrated downstream processing
• Vaccine and stem cell processing
• Validation & quality control (QbD)
Project based courses
Advanced Bioprocess Research
• Bioprocess research dissertation:
Projects range from biopharmaceuticals to chiral
biotransformations with both experimental and
modelling themes
Whole Bioprocess Management & Implementation
• Whole bioporcess practical studies
• Bioprocess analysis & presentation
• Bioprocess commercialisation
• Business planning for bioventures
Advanced Bioprocess Research
• Bioprocess research dissertation:
Projects range from biopharmaceuticals
to chiral biotransformations with both
experimental and modelling themes
10
Advanced Bioprocess Design
• Bioprocess creation & analysis
• Bioprocess design and economics
• Safety appraisal (HAZOP studies)
Validation & regulatory approval
List of Modules
COMPULSORY MODULES
Industrial Synthetic Biology
Sustainable Industrial Bioprocesses and Biorefineries
MEng BE Yr 4
Cell Therapy Bioprocessing
Bioprocess Systems Engineering
Bioprocess Research Project
MSc BE
Bioprocess Validation and Quality Control
OPTIONAL MODULES
Bioprocess Microfluidics
Vaccines Bioprocessing
Project Management
Process Dynamics and Control
Advanced Safety and Loss Prevention
Energy Systems and Sustainability
Advanced Process Engineering Advanced Process Modelling and Design
Routes
BEng Biochemical
Engineering
BEng Biochemical
Engineering
Industry
MSc Biochemical
Engineering (NEW)
MEng Biochemical
Engineering with
Bioprocess Management
MSc Biochemical
Engineering (NEW)
MEng Biochemical
Engineering with Study
Abroad
MEng Biochemical with
Chemical Engineering
Industry / PhD / EngD
11
Abbott Innovation
University
Challenge Success
A team made up of 4 UCL Biochemical Engineering students
(Freedanz Ferdinandz, Ali Versi, Udit Varma, Si U Sou) and 2
UCL Biotechnology students (Kheng Ng, Khai Kong) won 1st
prize in the 2012 Abbott Innovation University Challenge worth
$10,000. The team put forward a concept paper to address the
Abbott Challenge on: ‘Identification and support of patients with
pancreatic exocrine insufficiency’.
Below the team recount their experience:
“We decided to embark upon the Abbott challenge as we felt it was just up our
street having spent a significant amount of time during our degree dealing with
tasks related to the (bio-) pharmaceutical industry. This would be the sector
in which we were all hoping to work and therefore such an opportunity would
provide us with a taste of problems faced in the industry.
A choice of six projects was available to select from ranging from social media
application in clinical and business contexts to wild card ideas. We selected the
option which we felt was most relevant to Abbott’s current product line. Abbott
has already introduced a treatment for Pancreatic Exocrine Insufficiency into
the market - a pancreatic enzyme supplement, CREON®. However, diagnostics
which accurately confer dosage in a convenient manner are wanting. Our mission
was to generate ideas for diagnostics which remedies the current predicament.
The submission took the form of a concise concept paper detailing our ideas and
describing how they would be implemented into Abbott’s current portfolio in
addition to how the ideas would fair in the clinical environment. We provided a
range of ideas, starting with simple and cheap solutions with a short development
time, ranging to more complex solutions involving biosensors and biophysics
requiring a more significant development time.
As 3rd year students we already had a hefty schedule to conform to and
therefore we did not have enough time available for the submission as we would
have liked. Even though everyone contributed as much as he could we were
afraid that other competitors would create a better and more detailed product
due to more time available. So it was a fabulous surprise to hear a few weeks
later that we had been selected by the jury board to present our ideas to several
heads of departments of Abbott in Basel via teleconference. This meant that our
submission had come top in the UK and was in the top 5 globally.
After our presentation we received coaching based on the feedback from
the jury board of our submission and the feedback from the presentation.
12
The coaching was delivered by the head of gastroenterology and women’s
health at Abbott pointing out how the amalgamation of the scientific skills
of the biotechnology students with the engineering and business skills of the
biochemical engineers was one key to our success. He also gave valuable insights
into hurdles our ideas may face during manufacturing and regulation, which
drove us to opt for our simpler idea, which would forgo many issues taxing the
other ideas.
Upon receiving the feedback we had to resubmit our concept paper with
consideration of our coaching session. We also created an animation of our
chosen idea, showing its basic principle of function and its implementation in
the clinical environment. This was done during the exam period and close to the
submission deadline of the Biochemical Engineering Design Project- again we
had to reach our limits and push ourselves being motivated by our common aim:
winning the Abbott University Challenge 2012. And the harder and the more
we worked, we became more and more confident that we could actually make it
happen.
Our success was announced at the last day of our term (and for many the
end of their degree). We were sitting in the University London Union and
enjoying ourselves in an emotional but light-hearted atmosphere when the e-mail
notification caused deafening cheers for several minutes – a memorable moment.
It was appropriate that our final Design Project presentation and the
announcement of our victory fell on the same day since the challenge reflected
our journey through the third year as Biochemical Engineers - a journey full
of personal development where our staff of life was decidedness, patience,
dedication, persistence and motivation.
Yes - moments of hope and moments of desperation gave distinction to the
journey. A journey full of small battles – battles which resulted in personal
growth.
But most importantly it was a journey we didn’t have to take on our own and
where team-work was a major key to success.
The Abbott University Challenge was indeed not only an academically
enriching experience – it was moreover a bonding adventure with our close
friends and an appropriate completion of our fascination three years of university.
For further information, please contact Dr Suzy Farid at s.farid@ucl.ac.uk
13
GE Healthcare
UCL Biochemical Engineering and GE Healthcare have been working closely
together in a number of ways thanks to the drive and enthusiasm of UCL EngD
alumnus, Dr Naveraj Gill, who is now a ReadyToProcess Product Specialist
within GE Healthcare.
• The siting of GE’s ‘Ready to Rock’ Truck on Malet Place on the 23-25th
May. This enabled VISION Core Course delegates, members of the EPSRC
Centre for Emergent Macromolecular Therapies and the department’s EngD/
PhD students and academic staff to see in action the company’s Plug & Play
biomanufacturing with ReadyToProcess™ technologies.
• The Department also played host to a Microcarrier User Day on the 11th June.
This workshop, that made use of our Pilot Plant facilities, provided selected
postgraduates and industrialists an opportunity to gain further insight into
the use of microcarriers for cell culture processes in single-use bioreactors.
It comprised of a series of presentations with case study examples and a live
demonstration of microcarrier preparation for use with the WAVE™ bioreactor
system.
For more information about how to engage with us please contact Dr Karen
Smith at karen.smith@ucl.ac.uk
14
MBI® Module:
The MBI® Training
Programme is run by
the Department and
comprises a series of
UCL accredited short
courses in bioprocessing,
designed specifically
for industrialists. They
can be taken as standalone modules or can be
combined for certificate,
diploma or Masters
qualifications. To date
1,200 modules have
been taught to over 800
international delegates, and
more than 200 companies
have participated.
Cell to Column: Integrated
Solutions for Rapid
Processing of Biologics
(12-15 November 2012)
Learn how to select the best recovery options for
your bioprocess
This module focuses on the biological product recovery stage and, through a series
of lectures, case studies and pilot plant practical sessions, will enable you to:
• Understand the principles of all the major recovery operations: Centrifugation,
Membrane Systems, Filtration, Cell Disruption, Precipitation, Flocculation
• Compare unit operations for their suitability within a process and study them
in our unique pilot plant
• Determine the most appropriate equipment for separations and specify the
right operating conditions
• Learn to use Ultra Scale-Down tools for prediction of large scale separation
performance
• Understand the interaction between fermentation, recovery and purification
and learn how to locate the best the integrated solutions for bioprocess
development
Who should attend?
For further information please
email Dr Karen Smith at
karen.smith@ucl.ac.uk or see
http://www.ucl.ac.uk/
biochemeng/industry/mbi/
courses
This module is designed for scientists and engineers involved in design,
development and operation of primary recovery steps as well as those associated
steps in upstream and purification processes.
• Bioprocess developer
• R&D scientist
• Manufacturing technologist
• Manufacturing operational manager
A networking dinner will be held on the first evening. The module costs £1300.
Please contact mbi-training@ucl.ac.uk for further information.
15
Contacts
Research Sponsors:
Dr Karen Smith
Director of Bioprocess
Leadership
+44 (0)20 7679 4411
karen.smith@ucl.ac.uk
MBI®:
Mrs Liz Cullen
MBI® Manager
+44 (0)20 7679 1316
mbi-training@ucl.ac.uk
EPSRC Centre for
Emergent Macromolecular
Therapies:
Professor Nigel
Titchener-Hooker
+44 (0)20 7679 3796
nigelth@ucl.ac.uk
BiCE and Industrial
Doctoral Training Centre
(IDTC) for Bioprocess
Engineering Leadership:
Professor Gary Lye
+44 (0)20 7679 7942
g.lye@ucl.ac.uk
RegenMed Bioprocessing
Professor Chris Mason
+44 (0)20 7679 0140
chris.mason@ucl.ac.uk
MBI® course dates
2012–13
1 – 3 Oct 2012 Principles of Fermentation Processes
15 – 17 Oct 2012 Rapid Fermentation Process Design: From Development
to Manufacture
29 – 31 Oct 2012 Industrial Biotechnology and Biorefining
12 – 15 Nov 2012 Downstream processing:Cell to Column: Integrated Solutions for
Rapid Processing of Biologics
26 – 29 Nov 2012Downstream processing: Chromatography
5 – 7 Dec 2012 Vaccine Bioprocess Development and Commercialisation
28 – 30 Jan 2013 Current challenges in Mammalian Cell Processing
18 – 20 Feb 2013 Cell Therapy Bioprocessing
25 – 28 Feb 2013 Quality by Design for Effective Bioprocess Characterisation
and Validation
11 – 13 Mar 2013 Design of Experiments for Bioprocess Optimisation
3 – 6 June 2013 Bioprocess Design & Economic Evaluation
24 – 27 June 2013Bioprocess Facility Design
For more information, email mbi-training@ucl.ac.uk
Work with us
The UCL Advanced Centre for Biochemical Engineering actively encourages and
fosters long-term research partnerships between its academics and sponsors for
mutual benefit. We facilitate interaction in a range of ways, such as sponsor visits,
industrial advisory boards, Bioprocess Briefings, industrial placements for graduate
students and the MBI® Programme. Over 70 industrial and academic experts
contribute to our MBI® activities.
If you would like further information, please contact the appropriate member of
staff listed to the left.
16